Ipca Laboratories has reported a growth of 57.21 per cent in its net profit at Rs 41.38 crore for the October-December quarter of 2016. The pharmaceutical company had posted the net profit of Rs 26.32 crore in the corresponding quarter of previous fiscal, said Ipca Laboratories in a filing to BSE on Friday. The total revenue of company rose by 8.22 per cent to Rs 756.66 crore in Q3 FY17 from Rs 699.13 crore in Q3 FY16.
During the quarter under review, the operating income of the company grew by 23 per cent to Rs 110.39 crore from Rs 89.46 crore in the same period last year. Total formulations income was up 6 per cent at Rs 568.72 crore as compared to Rs 534.76 crore, while income from domestic market was Rs 335.24 crore, up 9 per cent year-on-year. Meanwhile, shares of company were trading at Rs 522.00 apiece, down 0.81 per cent, from previous close on the BSE at 13:10 hours.
SHARE and Stock Market Tips click here to subscribe us http://www.ripplesadvisory.com/free-trial.php
Ipca Laboratories has reported a growth of 57.21 per cent in its net profit at Rs 41.38 crore for the October-December quarter of 2016. The pharmaceutical company had posted the net profit of Rs 26.32 crore in the corresponding quarter of previous fiscal, said Ipca Laboratories in a filing to BSE on Friday. The total revenue of company rose by 8.22 per cent to Rs 756.66 crore in Q3 FY17 from Rs 699.13 crore in Q3 FY16.
During the quarter under review, the operating income of the company grew by 23 per cent to Rs 110.39 crore from Rs 89.46 crore in the same period last year. Total formulations income was up 6 per cent at Rs 568.72 crore as compared to Rs 534.76 crore, while income from domestic market was Rs 335.24 crore, up 9 per cent year-on-year. Meanwhile, shares of company were trading at Rs 522.00 apiece, down 0.81 per cent, from previous close on the BSE at 13:10 hours.
No comments:
Post a Comment